Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Shire surprises by tapping new CEO
Surprise! You're the next CEO. So said Shire to CFO Angus Russell (photo), who got an unexpected promotion to the company's top slot. The board moved present CEO Matt Emmens to non-executive chair, replacing James Cavanaugh, who retires in June. The changes won't take place until Cavanaugh's exit.
So who is Angus Russell? The 51-year old has been CFO at Shire since 1999, helping to usher the company through several mergers. Before that, he worked in finance, strategy, and marketing at several pharma companies, including AstraZeneca.
- check out Shire's statement
- read the report from MarketWatch
Related Articles:
New guard takes over Big Pharma. Report
Shire on lookout for acquisitions. Report
Shire to Massachusetts: Pass incentive bill now. Report
FDA approves Shire's new ulcerative colitis drug. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
